Haɓaka Tsarin Ci gaban Magunguna

Binciken da Kohler da Milstein suka yi na fasahar rigakafin ƙwayar cuta ta monoclonal (mAb) a cikin 1975 ya ba da damar ƙirƙirar ƙwayoyin rigakafi a matsayin nau'in warkewa (Kohler & Milstein, 1975).Monoclonal antibodies (mAbs) ɗaya ne daga cikin hanyoyin da ake amfani da su na miyagun ƙwayoyi don cututtuka masu yaduwa ko maganin ciwon daji saboda suna zaɓen ƙwayoyin cuta, ƙwayoyin cuta, ƙwayoyin cuta, har ma da ƙwayoyin rigakafi.Ta wannan hanyar, suna yin sulhu don kawar da kwayoyin da aka yi niyya da sel tare da ƙarancin illa fiye da sauran hanyoyin warkewa.Musamman, mAbs na warkewa na kansa na iya gane sunadaran-kwayoyin halitta akan ƙwayoyin da aka yi niyya sannan su kashe ƙwayoyin da aka yi niyya ta hanyoyi da yawa.
Halin ɗan adam yana rage yawan rigakafi na maganin warkewa a cikin ɗan adam, yana mai da yiwuwar gudanar da aiki na yau da kullun.Irin wannan ci gaban fasahar rigakafin mutum ya haifar da fashewa a cikin haɓakar mAbs na warkewa a cikin shekaru goma da suka gabata.Jerin abubuwan da suka samo asali, waɗanda suka haɗa da sunadaran Fc-fusion, magungunan antibody-drug conjugates (ADCs), immunocytokines (antibody-cytokine fusions), da antibody-enzyme fusions, kuma an haɓaka su kuma an daidaita su azaman sabon magani.